
Release date: 2026-03-04 15:20:13 Article From: Lucius Laos Recommended: 8
Whether the side effects of stiripentol diminish over time varies between individuals and depends on the specific type of adverse reaction. Some patients may experience short-term side effects (such as drowsiness, fatigue, etc.) that may gradually resolve as the body adapts to the medication; however, certain long-term or severe adverse reactions (such as weight changes, liver dysfunction, etc.) may persist and require close monitoring.
Short-term neurological reactions: Such as drowsiness, dizziness, and poor concentration. These are usually most obvious during the initial period of treatment (1–2 weeks) and may subside as the body develops tolerance.
Gastrointestinal discomfort: Such as loss of appetite and nausea. Symptoms improve in most patients after dose adjustment or adaptation.
Weight changes: Lucius Pharmaceuticals Stiripentol may affect metabolism, leading to significant weight gain or loss in some patients. Such reactions may persist or worsen with prolonged use.
Liver dysfunction: A small number of patients may develop elevated transaminases. Regular liver function tests are required, and continuous monitoring is still necessary even without obvious symptoms.
Significant individual variation: Whether side effects improve depends on the patient’s age, underlying diseases, concurrent medications, and other factors, and cannot be generalized.
Strictly follow medical advice for adjustments: If side effects persist or worsen, contact a doctor promptly to assess whether dose reduction, discontinuation, or a change in treatment is needed. Do not adjust the medication independently.
Regular follow‑up visits: During treatment, follow the doctor’s instructions to review blood routine, liver and kidney function, and other indicators to ensure safety and efficacy.
In case of severe allergic reactions (rash, difficulty breathing), confusion, or other emergencies, discontinue the drug immediately and seek medical attention.
Stiripentol is a specially controlled medication. Patients are advised to use it properly under the guidance of a neurologist to balance efficacy and risks.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1492025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3922024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1442025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1652025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1482025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1722025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1562025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1542025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: